Infosys Shares Jump on Buyback Demand
Infosys rose nearly 3 per cent to a high of Rs 3,608 on Wednesday after three former employees urged the IT major to buy back shares worth Rs. 11,200 crore. The stock ended as the top Nifty gainer and provided support to the bluechip indices on a day when markets came under selling pressure.
(Also read: Why Infosys ex-CFOs Want Rs 11,200 Crore Buyback)
Former Infosys CFOs T V Mohandas Pai and V Balakrishnan along with another former official D N Prahlad said the buyback will help check the "asymmetry of information" between management and investors. (Read the full story here)
"Infosys should immediately buy back its shares to the tune of Rs. 11,200 crore (which is roughly 40 per cent of the existing cash and cash equivalents)," the letter said.
The trio wants a buyback at the 52-week high price of Rs. 3,850 a share. They also want Infosys to announce an ongoing buyback programme to the extent of 40 per cent of the previous year's net profits on a consistent basis.
The letter said Infosys believed in increasing shareholders' wealth but in the past three years, its stock has heavily underperformed and has "resulted in wealth destruction".
Meanwhile, Infosys said, "The management receives requests on a variety of subjects from shareholders and investors on an ongoing basis. These are addressed by the board and the management in due course. In this particular case, we have received this request only from three retail investors."
Infosys shares closed 1.8 per cent higher at Rs 3,575.85, outperforming the broader Nifty, which fell nearly 1 per cent. Over the last week, Infosys shares have gained 6 per cent outperforming a 1 per cent gain in the IT sub-index on the BSE.
(With inputs from PTI)
-
Getting To Work Costs Women More | The Reason Why
It is not just about women paying more than men. It is about women paying much more in cities than in villages.
-
AI Bias In Investing Cannot Be Eliminated, But It Can Be Governed
Framing is a particularly important example as identical financial information presented in terms of gains rather than losses can lead an LLM to reach a different assessment.
-
Joining The Dots | Dark Skies, Steady Diya: Why Hope Holds This Diwali
With war, a weak rupee and foreign outflows weighing on sentiment, policymakers at the NDTV World Summit and market veterans at NDTV Profit Ignite: Diwali Edition offered the same advice: stay invested and filter out the noise.
-
The Curious Case of Equitas Small Finance Bank And A CEO Who Quit For Stock
PN Vasudevan believes persistent investor concerns over a perceived conflict of interest had become a governance overhang on Equitas Small Finance Bank's stock, even as the lender improved profitability and asset quality.
-
Talking Points This Week: AI Cash Burn, A Tiger Comeback And An India That Still Finds Its Own Path
India is not immune to higher oil or tighter global liquidity, yet its earnings base is broader, its domestic policy levers are still available.
-
Foreign Investors Own Half Of HDFC Bank and ICICI Bank. An LTCG Cut Could Matter Most Here
Foreign portfolio investors have US$115 billion parked in HDFC Bank, ICICI Bank. If the government cuts long-term capital gains tax, Jefferies says returning foreign money could land here first.
-
'Never Seen This Level Of Negativity': Sandeep Tandon Says The Next Rally May Be Closer Than You Think
Veteran investor Sandeep Tandon says foreign selling is easing, large-caps are due a comeback and mid-caps are crowded, while he turns positive on gold, power and pharma this Diwali.
-
Indians Stay With Family, Not In Hotels | The Reason Why
India still lacks enough clean, reliable and affordable hotels for budget-conscious travellers.
-
The Economic Imperative: Analysing The Material Driving Force Behind India-Canada Strategic Reset
This economic complementarity is further reinforced by deep institutional investment ties and talent mobility, which form the bedrock of the bilateral framework.
-
Medicine Pricing: Where Must Profit Stop?
India must confront excessive margins, hidden incentives and regulatory gaps that threaten the integrity of medicine.